chr12-13865843-G-C

Variant summary

Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_000834.5(GRIN2B):​c.366C>G​(p.Pro122Pro) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.409 in 1,612,878 control chromosomes in the GnomAD database, including 136,826 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.42 ( 13790 hom., cov: 31)
Exomes 𝑓: 0.41 ( 123036 hom. )

Consequence

GRIN2B
NM_000834.5 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:11

Conservation

PhyloP100: 2.94
Variant links:
Genes affected
GRIN2B (HGNC:4586): (glutamate ionotropic receptor NMDA type subunit 2B) This gene encodes a member of the N-methyl-D-aspartate (NMDA) receptor family within the ionotropic glutamate receptor superfamily. The encoded protein is a subunit of the NMDA receptor ion channel which acts as an agonist binding site for glutamate. The NMDA receptors mediate a slow calcium-permeable component of excitatory synaptic transmission in the central nervous system. The NMDA receptors are heterotetramers of seven genetically encoded, differentially expressed subunits including NR1 (GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, or GRIN2D) and NR3 (GRIN3A or GRIN3B). The early expression of this gene in development suggests a role in brain development, circuit formation, synaptic plasticity, and cellular migration and differentiation. Naturally occurring mutations within this gene are associated with neurodevelopmental disorders including autism spectrum disorder, attention deficit hyperactivity disorder, epilepsy, and schizophrenia. [provided by RefSeq, Aug 2017]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.51).
BP6
Variant 12-13865843-G-C is Benign according to our data. Variant chr12-13865843-G-C is described in ClinVar as [Benign]. Clinvar id is 129205.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr12-13865843-G-C is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=2.94 with no splicing effect.
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.483 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
GRIN2BNM_000834.5 linkuse as main transcriptc.366C>G p.Pro122Pro synonymous_variant 3/14 ENST00000609686.4 NP_000825.2 Q13224A0A8D9PHB2

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
GRIN2BENST00000609686.4 linkuse as main transcriptc.366C>G p.Pro122Pro synonymous_variant 3/141 NM_000834.5 ENSP00000477455.1 Q13224
GRIN2BENST00000630791.2 linkuse as main transcriptc.366C>G p.Pro122Pro synonymous_variant 4/85 ENSP00000486677.3 A0A0D9SFK0

Frequencies

GnomAD3 genomes
AF:
0.421
AC:
63823
AN:
151732
Hom.:
13774
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.489
Gnomad AMI
AF:
0.201
Gnomad AMR
AF:
0.342
Gnomad ASJ
AF:
0.401
Gnomad EAS
AF:
0.474
Gnomad SAS
AF:
0.497
Gnomad FIN
AF:
0.395
Gnomad MID
AF:
0.310
Gnomad NFE
AF:
0.397
Gnomad OTH
AF:
0.394
GnomAD3 exomes
AF:
0.408
AC:
102530
AN:
251152
Hom.:
21587
AF XY:
0.413
AC XY:
56114
AN XY:
135726
show subpopulations
Gnomad AFR exome
AF:
0.499
Gnomad AMR exome
AF:
0.295
Gnomad ASJ exome
AF:
0.375
Gnomad EAS exome
AF:
0.491
Gnomad SAS exome
AF:
0.498
Gnomad FIN exome
AF:
0.402
Gnomad NFE exome
AF:
0.397
Gnomad OTH exome
AF:
0.389
GnomAD4 exome
AF:
0.408
AC:
596152
AN:
1461028
Hom.:
123036
Cov.:
43
AF XY:
0.411
AC XY:
298613
AN XY:
726844
show subpopulations
Gnomad4 AFR exome
AF:
0.489
Gnomad4 AMR exome
AF:
0.304
Gnomad4 ASJ exome
AF:
0.379
Gnomad4 EAS exome
AF:
0.470
Gnomad4 SAS exome
AF:
0.495
Gnomad4 FIN exome
AF:
0.407
Gnomad4 NFE exome
AF:
0.402
Gnomad4 OTH exome
AF:
0.413
GnomAD4 genome
AF:
0.421
AC:
63881
AN:
151850
Hom.:
13790
Cov.:
31
AF XY:
0.421
AC XY:
31253
AN XY:
74234
show subpopulations
Gnomad4 AFR
AF:
0.488
Gnomad4 AMR
AF:
0.343
Gnomad4 ASJ
AF:
0.401
Gnomad4 EAS
AF:
0.475
Gnomad4 SAS
AF:
0.496
Gnomad4 FIN
AF:
0.395
Gnomad4 NFE
AF:
0.397
Gnomad4 OTH
AF:
0.394
Alfa
AF:
0.400
Hom.:
3958
Bravo
AF:
0.418
Asia WGS
AF:
0.488
AC:
1697
AN:
3478
EpiCase
AF:
0.388
EpiControl
AF:
0.389

ClinVar

Significance: Benign
Submissions summary: Benign:11
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:6
Benign, criteria provided, single submitterclinical testingGeneDxOct 24, 2013This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
Likely benign, no assertion criteria providedclinical testingGenetic Services Laboratory, University of Chicago-Likely benign based on allele frequency in 1000 Genomes Project or ESP global frequency and its presence in a patient with a rare or unrelated disease phenotype. NOT Sanger confirmed. -
Benign, no assertion criteria providedclinical testingJoint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+-- -
Benign, criteria provided, single submitterclinical testingUnidad de Genómica Garrahan, Hospital de Pediatría GarrahanJul 15, 2024This variant is classified as Benign based on local population frequency. This variant was detected in 44% of patients studied in a panel designed for Epileptic and Developmental Encephalopathy and Progressive Myoclonus Epilepsy. Number of patients: 41. Only high quality variants are reported. -
Benign, no assertion criteria providedclinical testingDiagnostic Laboratory, Department of Genetics, University Medical Center Groningen-- -
Benign, criteria provided, single submitterclinical testingEurofins Ntd Llc (ga)Jun 07, 2017- -
Inborn genetic diseases Benign:1
Benign, criteria provided, single submitterclinical testingAmbry GeneticsJan 08, 2016This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Intellectual disability, autosomal dominant 6;C4015316:Developmental and epileptic encephalopathy, 27 Benign:1
Benign, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpFeb 01, 2024- -
not provided Benign:1
Benign, criteria provided, single submitternot providedBreakthrough Genomics, Breakthrough Genomics-- -
Intellectual disability, autosomal dominant 6 Benign:1
Benign, criteria provided, single submitterclinical testingGenome-Nilou LabAug 10, 2021- -
Developmental and epileptic encephalopathy, 27 Benign:1
Benign, criteria provided, single submitterclinical testingGenome-Nilou LabAug 10, 2021- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.51
CADD
Benign
5.3
DANN
Benign
0.63

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs7301328; hg19: chr12-14018777; COSMIC: COSV74205708; COSMIC: COSV74205708; API